about
The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell ApoptosisMVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesionsClass III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancerγ-Actin plays a key role in endothelial cell motility and neovessel maintenanceTubulin proteomics: towards breaking the code.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancerTargeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma.Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.Understanding microtubule dynamics for improved cancer therapy.Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization.Microtubule-targeting agents in angiogenesis: where do we stand?Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.Microtubules: a dynamic target in cancer therapy.Can targeted therapy be successful without metronomic scheduling?Has the time come for metronomics in low-income and middle-income countries?Metronomics: towards personalized chemotherapy?Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside StudySynthesis, biological evaluation and structure-activity relationship studies of isoflavene based Mannich bases with potent anti-cancer activity.Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes.Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.γ-Actin regulates cell migration and modulates the ROCK signaling pathway.Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?Caulerpenyne-colchicine hybrid: synthesis and biological evaluation.Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties.Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis.Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens.Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.Paediatrics: Metronomics - fulfilling unmet needs beyond level A evidence.Investment in cancer studies in countries of low and middle income.For cancer, seek and destroy or live and let live?Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.Metronomics during palliative care in paediatric oncology? For sure! But handle me with care
P50
Q22248069-F966F02C-39D1-4108-A2A2-9E444BBB939EQ27331610-C702CB45-9063-466E-8413-6042A7668A5EQ28251547-33CDC2AC-A688-4F3B-AE67-49C0AE96C655Q30620886-673B8EAE-1BF3-4338-867A-FA2A9932286DQ33687990-4FEBDD66-2563-4092-9327-AF7ED2522E79Q34173001-DB2D2061-7C71-4C3B-8B65-409C109725EBQ34618624-0125EA7E-1698-4CFB-99D7-83E3291519F9Q35002582-8AAE41EB-0C8C-446D-A3BA-660987B60020Q35116804-D8678084-2750-4F72-A47A-944C6EB3A70DQ36325621-17B17B5D-4D68-4995-9346-2F8B4C1C8B3CQ36406772-D1F4BE59-7E1C-4FED-B3CD-04D192034ADBQ36484101-93094556-7F60-4040-A94B-8CFD21B82FA2Q36952063-C642C062-EB90-422E-B4C8-C036248F9353Q36959073-E1CB02BD-BD1F-40F1-8D81-F1511C3B83C4Q36962372-50A93E56-46D5-43DD-A0FA-53E410B12E2AQ37124695-4DC49859-2923-4BE6-A6CC-80EBBC8B3DE7Q38043504-B5690D02-0987-4003-9BFD-91286D7DA814Q38103647-295E14E3-B589-49EA-A30F-9C3E84E443CFQ38218923-1E9C9D42-ED67-457D-A9D1-D95052F6470CQ38585005-2BF52034-B9BE-42C5-BDE1-30B2F3E327A7Q38769283-C124A786-D245-4025-9C8A-09FC5C01D2A0Q38830692-58CF923D-9485-4EA1-856F-6736B19479B5Q38959727-B5DE1F3D-7812-4738-BBB9-FBDA469088C5Q39185073-2B9DC4E4-D465-49F3-9A30-50D3A1C60E5AQ39475999-F4F8C244-9528-4D5F-BC43-3D839845FE69Q39770387-B1B1C238-BA48-4893-9A3C-CBB07DA71AC5Q40277401-169CBDE1-ABC3-4175-B3E2-DD3FB7A67610Q40444048-EBEEA436-9C5F-4790-8BBB-163A0BAFEBACQ42957826-26DC4FA5-38CA-4393-9854-455E3B94C97AQ43074233-E6937950-D986-4624-92DE-27FD24E1337CQ46012949-3672303A-C66C-4410-B69B-090DD0DE0350Q46368635-0C0B1AE6-6797-46F2-8D71-ACF306451149Q46416734-B4B93841-2399-41C2-9B3B-7C196983C964Q46436937-6BB35556-BC6C-4C9E-9D64-3622E43DC264Q46685452-464B09A7-1E3B-4ADD-82E5-E4EC986B69B2Q47713914-E9A67404-5A2B-400E-9B25-D0A0F593F126Q47857466-1D879EA6-2C35-4A7B-86B7-AE57BE7FEFB2Q53383454-18A74FF5-7E45-4E04-97CC-41AF9155529FQ53632268-9CA6C6AB-02CA-4023-84C6-2759D0086DC9Q59269449-5F58E2C8-80C4-4D7C-B546-973F6B2C49E8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eddy Pasquier
@ast
Eddy Pasquier
@en
Eddy Pasquier
@es
Eddy Pasquier
@sl
type
label
Eddy Pasquier
@ast
Eddy Pasquier
@en
Eddy Pasquier
@es
Eddy Pasquier
@sl
prefLabel
Eddy Pasquier
@ast
Eddy Pasquier
@en
Eddy Pasquier
@es
Eddy Pasquier
@sl
P106
P1153
10244895000
P21
P31
P496
0000-0003-2824-5002